Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51 - Trial NCT06390098
Access comprehensive clinical trial information for NCT06390098 through Pure Global AI's free database. This Phase 1 trial is sponsored by Asceneuron S.A. and is currently Completed. The study focuses on Alzheimer Disease. Target enrollment is 3 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Asceneuron S.A.
Timeline & Enrollment
Phase 1
Aug 09, 2021
Nov 02, 2021
Primary Outcome
Pharmacodynamic (PD) change of [18F]-IMA601 regional total volume of distribution (VT) at each brain scan
Summary
This is a phase 1, open-label, PET study in healthy adult subjects to determine the
 relationship between plasma concentration and brain target occupancy of ASN51 following a
 single oral dose.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06390098
Non-Device Trial